Results 181 to 190 of about 12,784,255 (313)

Metabolic disorders associated with the use of targeted cancer therapies

open access: yes, 2015
Purpose of review The everyday use of targeted therapies, whose mechanisms of action differ from the conventional cytotoxic agents, also causes the emergence of new toxicities as metabolic disorders about which little is known.
Awada, Ahmad   +2 more
core   +1 more source

Smaller is better: nanobodies meet NMR

open access: yesFEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Changes in sexual-function scores after washed microbiota transplantation in men with sexual dysfunction: an exploratory single-arm pre–post observational study

open access: yesFrontiers in Microbiology
Background and aimsCurrent therapies for male sexual dysfunction (MSD) exhibit variable efficacy and potential adverse effects. Washed microbiota transplantation (WMT) is an emerging microbiota-based intervention, but its clinical relevance to MSD ...
Junyi Chen   +18 more
doaj   +1 more source

Targeting the value of targeted therapy

open access: yesOncotarget, 2017
Paggio, Joseph C. Del   +2 more
openaire   +2 more sources

Targeted Therapy in Oncology [PDF]

open access: yesMedical Journal Armed Forces India, 2006
B K, Mishra, Purvish M, Parikh
openaire   +2 more sources

Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis

open access: yesFEBS Letters, EarlyView.
This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng   +8 more
wiley   +1 more source

Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells

open access: yesFEBS Letters, EarlyView.
DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park   +8 more
wiley   +1 more source

Washed microbiota transplantation relieves atopic dermatitis via gut–skin microbiome rebalancing

open access: yesBMC Microbiology
Background Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease in which dysbiosis of gut and skin microbiota contributes to pathogenesis and severity.
Wanying Deng   +6 more
doaj   +1 more source

Application of nanotechnology and micro/nanorobots in thrombotic diseases

open access: yesEngMedicine
Thrombotic diseases, a class of circulatory system disorders characterized by the abnormal coagulation of blood within arterial and venous vessels, leading to partial or complete vascular occlusion, represent a major global cause of mortality and ...
Siqi Lv, Liang V. Tang, Yu Hu
doaj   +1 more source

Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies

open access: yes, 2017
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common causes of disability in young adults. Over the last decade, new disease-modifying therapies have emerged, including monoclonal antibodies (mAbs) that provide
Marshall, T   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy